FDA’s "Complete Response" Letters May Not Be Complete Enough For Firms
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's "complete response" final regulations finally do away with negative connotations of the "not approvable" label used by the agency since the 1990s, but they will not provide more certainty for sponsors about how to answer FDA's problems with an application
You may also be interested in...
Tracking Troubled NDAs: New FDA Regs Mean Less Clarity For Investors
After an 11-year process, FDA is doing away with “approvable” and “not approvable” letters. The new name (“complete response”) gets rid of the negative connotations of “not approvable.” But it is likely to create more confusion – and less transparency – for investors and the public
FDA May Defer Review Of Amendments Under "Complete Response" Reg
FDA’s proposed "complete response" regulation gives the agency the discretion to defer review of an amendment until a subsequent review cycle.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.